Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncol Rep. 2014 Aug;32(2):829-34. doi: 10.3892/or.2014.3227. Epub 2014 May 30.

Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.

Author information

1
Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan.
2
Department of Molecular Cell Biology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
3
Department of Molecular Immunology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan.
4
Department of Surgery, Jikei University School of Medicine, Tokyo, Japan.
5
Institute of DNA Sciences, Yokohama, Japan.

Abstract

Cholangiocarcinoma is a disease with a poor prognosis. A human cholangiocarcinoma cell line, TK, was previously established to enable further understanding of the disease. We conducted this investigation to determine whether or not the TK line is useful for pharmacokinetic study of the chemotherapeutic agent gemcitabine (GEM). Along with the BXPC3 human pancreatic adenocarcinoma cell line, the sensitivity to and effects on the TK cell line of GEM were compared. The influence of deoxycytidine kinase (dCK) transduction was also comparatively investigated. The effects of GEM in terms of drug sensitivity of the TK cell line, cell cycle and levels of transcripts of key enzymes were comparable to the BXPC3 cell line. Responses to the drug were similar in both cell lines. In contrast to pancreatic carcinoma, cell lines for research on cholangiocarcinoma have been limited. This study suggests the application of the TK cell line to the pharmacokinetic study of the chemosensitization of therapeutic drugs, such as GEM.

PMID:
24891233
DOI:
10.3892/or.2014.3227
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Spandidos Publications
    Loading ...
    Support Center